About
About Japan Tissue Engineering Co., Ltd
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Contract, and Lab Site Project segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it offers EPI-MODEL, a reconstructed human epidermis model. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. operates as a subsidiary of Teijin Limited.
Visit company website
5 years, 5 months ago
Japan Tissue Engineering Co., Ltd is currently in a long term uptrend where the price is trading 7.7% above its 200 day moving average.
From a valuation standpoint, the stock is 80.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.9.
Japan Tissue Engineering Co., Ltd's total revenue sank by 10.6% to $466M since the same quarter in the previous year.
Its net income has dropped by 50.3% to $-138M since the same quarter in the previous year.
Based on the above factors, Japan Tissue Engineering Co., Ltd gets an overall score of 2/5.